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Abstract
Accurate prediction of drug-target interaction (DTI) is essential for in silico drug
design. For the purpose, we propose a novel approach for predicting DTI using a GNN
that directly incorporates the 3D structure of a protein-ligand complex. We also apply
a distance-aware graph attention algorithm with gate augmentation to increase the per-
formance of our model. As a result, our model shows better performance than docking
and other deep learning methods for both virtual screening and pose prediction. In ad-
dition, our model can reproduce the natural population distribution of active molecules
and inactive molecules.
1
ar
X
iv
:1
90
4.
08
14
4v
1 
 [c
s.L
G]
  1
7 A
pr
 20
19
Introduction
Accurate prediction of drug-target interaction (DTI) is essential for in silico drug discov-
ery. Thanks to the revolutionary development of theories and the required computational
power, calculation methods—such as molecular dynamics and quantum mechanics/molecular
mechanics—show reliable performance for calculating the binding free energy between a lig-
and and a protein.1,2 Though the accuracy of such methods is close to chemical accuracy,
their huge computational costs impede their routine usage. On this ground, molecular dock-
ing has been developed to predict the binding affinity with affordable computational costs
and reliable accuracy.3–10 Molecular docking greatly reduces computational costs through
principled parameter fitting, and as a result, it is fast enough to be practically used. De-
spite this advantage, however, the accuracy of docking is often insufficient to find novel drug
candidates from huge molecular libraries.
More recently, deep learning techniques11 have attracted much attention as a promising
alternative for calculating DTI. While various machine learning techniques have already
been utilized to improve the performance of DTI calculation, deep learning techniques in
particular have clear advantages over conventional approaches. Deep learning techniques
can automatically extract task-related features from a huge database without handcrafted
features or rules. In addition, the huge expressive power of deep learning techniques enables
efficient training with a large amount of data. Such advantages are particularly important
in, for instance, biological and chemical applications, where the sizes of the databases are
exponentially growing.12
Wallach et al. were first to introduce a deep learning based method for predicting DTI.13
In their work, the atomic coordinates of a protein-ligand complex around the binding site
are represented on a 3D rectangular grid. Then, a 3D convolutional neural network is applied
to the rectangular grid to classify whether the complex is active or not. As a result, their
model outperformed docking in terms of the area under the receiver operating characteristic
(AUROC) and the adjusted LogAUC.14 Ragoza et al. used a similar neural network structure
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to extend the above approach to classify not only active and inactive ligands but also active
and inactive binding poses.15 For both classification tasks, the 3D convolutional neural net-
work outperformed docking, RF-score,16 and NNScore.17 Also, 3D deep convolutional neural
networks can improve the accuracy of predicting absolute binding affinities18,19 compared to
classical scoring functions such as RF-Score,16 X-Score,20 and Cyscore.21
Another set of approaches independently expresses a ligand and a protein without 3D
binding structures between them. A common framework is to integrate the vectors represent-
ing each of the ligand and the protein within a neural network such as a siamese network.
The main advantage of these approaches is that they do not require binding poses, whose
high-quality data is limited.
Karimi et al. developed a method named DeepAffinity to predict the pIC50 of a given
protein-ligand complex with only the sequence of the protein and the SMILES of the ligand.22
They also interpreted how their model treats the interaction between ligands and proteins
using an autoencoder, which is jointly trained with the prediction model. In spite of the
advantage that their model doesn’t require 3D geometry data, the performance significantly
dropped for the test set where both ligands and proteins were not included in the training
set. Gao et al. developed a method for predicting DTI based on a siamese network composed
of a graph convolutional neural network and a recurrent neural network.23 They analyzed
how their model learns protein-ligand interactions with attention algorithm. Oztürk et al.24
and Lee et al.25 proposed a method based on 1D deep convolutional neural networks with
representing a ligand as a SMILES and a protein as a sequence. Additionally, it is reported
that a neural fingerprint specialized in DTI prediction can increase the accuracy of DTI
models compared to conventional fingerprints.26
Accurately representing protein-ligand complexes is critical for the performance of DTI
models and determines the corresponding neural network architecture. Furthermore, the rep-
resentation of protein-ligand complexes determines which dataset should be used and how
to preprocess it. Graph representation of molecules, where atoms and chemical bonds corre-
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spond to nodes and edges respectively, is a natural and compact way of describing molecular
structures. Sophisticated graph neural networks (GNNs)27–32 with graph representation of
molecules showed remarkable performance for predicting various molecular properties.
The success of GNNs in predicting molecular properties suggests the graph neural net-
work as a promising architecture for improving DTI models. Indeed, Gomes et al. developed
an atomic convolutional neural network (ACNN) by defining the atom type convolution and
the radial pooling layer.33 Feinberg et al. proposed a spatial graph convolution, applying
different graph convolution filters based on the Euclidean distances between atoms.34 Torng
et al. developed a two-step graph convolutional framework for predicting DTI.35 Motivated
by these recent results, we further develop ways to improve GNN based DTI models. One
way of achieving this is to devise a graph representation of 3D binding structures for cor-
rectly capturing intermolecular interactions. In accordance with the new representation, a
corresponding neural network architecture should be designed.
In this paper, we propose a novel approach for predicting DTI using a GNN that directly
incorporates the 3D structure of a protein-ligand complex. This allows us to not only clas-
sify active and inactive compounds but also distinguish active and inactive binding poses.
No heuristic chemical rules were used to deal with noncovalent interactions. Our GNN also
includes a graph attention mechanism,36 which allows us to model the intrinsic nature of a
protein-ligand complex: specifically, interactions between ligand atoms and protein atoms do
not contribute equally to their binding affinity. Additionally, we improve the performance of
our model by adopting a gate augmentation mechanism.37 As a result, our method outper-
formed docking and previous deep learning methods in terms of both virtual screening and
pose prediction. We also show that our model can reproduce the natural population distri-
bution of active and inactive molecules. Finally, we analyzed the limitations of our model’s
generalization ability using an external molecular library.
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Method
In terms of methodology, our contribution can be summarized in three parts: embedding
the 3D structure of a protein-ligand complex in an adjacency matrix, devising attention
algorithm considering 3D structures, and introducing a variant of graph neural networks
that is suitable for learning protein-ligand interaction. Each part will be described in the
following subsections. Before explaining our contributions, we will briefly introduce graph
neural networks. Finally, we will explain which datasets are used and how to preprocess
them.
Graph neural network
Graphs can be defined by (V , E, A), where V is a set of nodes, E is a set of edges, and A is
an adjacency matrix. In an attributed graph, the attribute of each node is usually represented
by a vector. The adjacency matrix is an N ×N matrix, where Aij > 0 if i-th and j-th nodes
are connected and Aij = 0 otherwise. N denotes the number of nodes in the graph. Graph
neural networks (GNNs) which operate on graphs have been explored in a diverse range of
domains and have shown remarkable performance in various applications.38 Also, various
architectures of GNNs have been developed.27–32
In general, GNNs are composed of three stages: i) updating node features, ii) aggregating
the node features and processing graph features, and iii) predicting a label of the graph.39
In the first stage, the node feature xi, representing attributes of the i-th node, is updated
over several times of message passing between neighboring nodes. This stage aims to obtain
high level representations of node features. Then, the updated node features are aggregated
to produce graph features. Here, the result of the aggregation must be invariant over permu-
tations of node ordering. Finally, the graph features are used to predict a label of the entire
graph, for instance molecular properties.
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Embedding the 3D structure of a protein-ligand complex
To correctly predict drug-target interactions (DTIs), it is important to describe the 3D
binding structure of a protein-ligand complex in a graph. The reason is that the 3D binding
structure determines physical, chemical, and biological properties of complexes including
intermolecular interactions. We embed the distance information between protein and ligand
atoms in two adjacency matrices, A1 and A2. A1 represents purely covalent interactions,
andA2 represents both covalent interactions and noncovalent intermolecular interactions. By
constructing two adjacency matrices, we let our model learn how protein-ligand interactions
affect the node feature of each atom. A1 and A2 are constructed as follows:
A1ij =

1 if i and j is connected by covalent bond or i=j
0 otherwise
(1)
A2ij =

A1ij if i, j ∈ protein atoms or i, j ∈ ligand atoms
e−(dij−µ)
2/σ if dij < 5 and i ∈ ligand atoms and j ∈ protein
atoms, or if dij < 5 and i ∈ protein atoms and
j ∈ ligand atoms
0 otherwise
(2)
where dij is the distance between the i-th and j-th atoms, and µ and σ are learnable pa-
rameters. The form e−(dij−µ)2/σ in Eq. 2 reflects that intermolecular bonds are weaker than
covalent bonds and that their strengths are getting weaker as the bond distance increases.
Representing 3D structures in an adjacency matrix has advantages over grid represen-
tation. In grid representation, a large amount of empty grid points can cause unnecessary
computation and memory usages. Also, grid representation can lose distance information
between atoms depending on the grid spacing. Furthermore, because it is not rotationally
invariant, rotating atomic coordinates changes the prediction value of binding affinity. In con-
trast, our graph representation is compact and rotationally invariant. In addition, it enables
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efficient expression of the exact distance between atoms.
A distance-aware graph attention mechanism
The inputs of our graph attention layer are adjacency matrix, A, and the set of node features,
xin = {xin1 , xin2 , ..., xinN } with x ∈ RF , where N is the number of nodes (i.e the number of
atoms). F is the dimension of the node feature. The graph attention layer produces a new
set of node features xout = {xout1 , xout2 , ..., xoutN } with x ∈ RF . In order to achieve sufficient
expressive power, each node feature is transformed by a learnable weight matrix W ∈ RF×F
such that x′i =Wxini . Then, the attention coefficient, eij, is obtained as follow:
eij = x
′T
i Ex
′
j + x
′T
j Ex
′
i, (3)
where E ∈ RF×F is also a learnable matrix. The attention coefficient, eij, represents the
importance of the j-th node feature to the i-th node feature. We forced eij = eji by summing
x′Ti Ex′j and x′Tj Ex′i. To reflect graph structure, the attention coefficient, eij, is computed only
for j ∈ Ni, where Ni is the neighborhood of the i-th node. We define Ni as the set of nodes of
which Aij > 0 because our adjacency matrix reflects both connectivity and the normalized
distance. To manipulate the scale of the attention coefficients across nodes, the attention
coefficient is normalized across neighbors. Additionally, we multiply Aij to the normalized
attention coefficients to reflect that a node with a shorter Euclidean distance is more likely
to be important than the others. It can be considered as an inductive bias. Consequently,
the normalized attention coefficient, aij, is given by
aij =
exp(eij)∑
j∈Ni exp(eij)
Aij. (4)
After the normalized attention coefficient, aij, is obtained, each node feature is updated
as a linear combination of the node features of the neighboring nodes with the normalized
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attention coefficient:
x′′i =
∑
j∈Ni
aijx
′
j. (5)
We also augment a gate mechanism to directly deliver information of the previous node
features to the next layer. It is found that a gate augmentation algorithm significantly im-
proves the performance of a model.37 We implement the output of our gated graph attention
layer as a linear combination of x′ and x′′ as follows:
xouti = zix
′
i + (1− zi)x′′i (6)
with
zi = σ(U(xi‖x′i) + b), (7)
where U ∈ R2F×1 is a learnable vector, b is a learnable scalar value, σ denotes a sigmoid
activation function, and (·‖·) is a concatenation of two vectors. zi can be interpreted as how
much information of input node features will be directly delivered to the next layer.
Neural network architecture
The inputs of our neural network are x, A1, and A2. Two new node features, x1 and x2,
are produced by the gate augmented graph attention layer respectively with A1 and A2,
i.e., x1 = GAT (x,A1) and x2 = GAT (x,A2), where GAT is the gate augmented graph
attention layer. It should be noted that one gate augmented graph attention layer is shared
when computing x1 and x2. The output node feature, xf , is obtained by subtracting x1 from
x2:
xout = x2 − x1. (8)
8
By subtracting the two node features, x2 and x1, we let our model learn the difference between
the structure when a ligand binds to a protein and the structure when they are separated.
After the feature vectors are updated by several gate augmented graph attention layers,
the feature vectors are summed into one vector representing the graph of the protein-ligand
complex:
xgraph =
N∑
i=1
xi. (9)
Finally, multi-layer perceptrons are applied to xgraph to classify whether the protein-ligand
complex or the binding pose is active or not. ReLU activation functions are used between
the layers, and a sigmoid function is used after the last layer.
Dataset preparation
We used the DUD-E40 and PDBbind41 v.2018 datasets to train and test our model. 72
proteins and 25 proteins in the DUD-E set were used to train and test the model, respectively.
To remove undesirable redundancy, we divided the dataset in a way that no protein is present
both in the training set and in the test set. The 3D binding structures of protein-ligand
copmlexes were obtained from docking calculations.
The PDBbind dataset, which provides experimentally verified binding structures of protein-
ligand complexes, was used to train our model to distinguish active and inactive binding
poses. For each sample in the PDBbind dataset, we performed docking calculation to gener-
ate possible binding poses of the protein-ligand complex. A generated pose was labeled as a
positive sample if the root mean square deviation (RMSD) from its experimentally verified
binding structure is less than 2 Å and labeled as a negative sample if the RMSD is larger than
4 Å. The samples whose RMSD is between 2 Å to 4 Å were omitted. Then, the PDBbind
dataset was splitted into a training set and a test set depending on the protein so that the
training and the test sets don’t share common proteins. Additionally, the PDBbind samples
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whose protein is included in the DUD-E dataset were removed from both the training and
the test sets.
The statistics of our training and test sets is summarized in Table 1. As Table 1 shows, the
inactive samples and DUD-E samples are much more abundant in the training set and the test
set compared to the active samples and PDBbind samples. To deal with such imbalance of
the datasets, we sampled DUD-E active, DUD-E inactive, PDBbind positive, and PDBbind
negative samples with the fixed ratio of 1:1:1:1 in constructing one training batch.
Table 1: Number of the training and the test samples for DUD-E active, DUD-E inactive,
PDBbind positive, and PDDbind negative.
DUD-E active DUD-E inactive PDBbind positive PDBbind negative
training 15864 973260 1598 9511
test 5841 364149 496 2735
All the 3D binding structures of protein-ligand complexes were obtained using Smina,42
the fork of AutoDock Vina,10 even when experimental 3D structures are available, to main-
tain consistency. For the DUD-E dataset, the default setting of Smina was used. Exhaus-
tiveness=50 and num modes=20 were used for docking calculations of the PDBbind dataset.
After the docking calculations were completed, the protein atoms whose minimum distance
to the ligand atoms is larger than 8 Å were excluded to remove unnecessary atoms in the
graph representation of protein-ligand complexes.
We represent initial atom features as a vector of size 56. The 1st–28th entities represent
ligand atoms and the 29th–56th entities represent protein atoms. The list of the initial atom
features is summarized in Table 2. Our model consists of four gate augmented graph attention
layers and three fully connected layers. The dimension of the graph attention layers was 140,
and that of the fully connected layers was 128. We trained our model for 150,000 iterations
with the batch size of 32. To avoid overfitting, we applied dropout with the rate of 0.3 to
every layer except the last of the fully connected layers.
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Table 2: The list of atom features
atom type C, N, O, S, F, P, Cl, Br, B, H (onehot)
degree of atom 0, 1, 2, 3, 4, 5 (onehot)
number of hydrogen atoms attached 0, 1, 2, 3, 4 (onehot)
implicit valence electrons 0, 1, 2, 3, 4, 5 (onehot)
aromatic 0 or 1
Results and discussion
Performance on the DUD-E and PDBbind test set
The performance of structure-based virtual screening can be assessed by measuring the ability
to classify active and inactive compounds. We compared the performance of our models
with docking and other deep learning based models in terms of AUROC, adjusted LogAUC,
and PRAUC. We calculated the AUROC, adjusted LogAUC, and PRAUC of our model by
averaging their values of each protein to balance data inequality between the proteins.
Table 3 summarizes AUROC, adjusted LogAUC, and PRAUC values of our model, dock-
ing, and other deep learning methods for the DUD-E test set. Among various deep learning
models, we chose the deep learning models trained using the DUD-E dataset for fair com-
parison. Though all the models used the one same dataset, we note that the exact division
of the training and test sets is different over the models. Table 3 clearly shows that our
GNN-based method outperformed the other deep learning models as well as docking. Our
model achieved AUROC of 0.968 compared to 0.689 of docking and 0.85–0.9 of other deep
learning models. In addition, our model achieved high PRAUC value of 0.697 for the DUD-E
test set, where the decoy molecules are much dominant than the active molecules.
We also analyzed ROC enrichment (RE)43,44 score and summarized it in Table 4. The RE
score indicates the fraction of the true positive rate (TPR) to the false positive rate (FPR) at
a certain FPR value. In terms of the RE score, our method is 5–6 times better than docking
and 1.5–2 times better than other deep learning based models. Also, the distance-aware
attention algorithm clearly improved the performance in virtual screening for all metrics.
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Generally, in hit discovery, only top hundreds of molecules are selected and tested through
experiments. So the better performance on LogAUC and RE score indicates a practical
advantage of our model when screening a large molecule set.
Table 3: AUROC, adjusted LogAUC, and PRAUC of our model, docking, and other deep
learning models. We note that the exact division of the training and test sets is different
over the models.
AUROC adjusted LogAUC PRAUC
ours 0.968 0.633 0.697
ours w/o attention 0.936 0.577 0.623
docking 0.689 0.153 0.016
Atomnet13 0.855 0.321 -
Ragoza et al.15 0.868 - -
Torng et al.35 0.886 - -
Gonczareket al.26 0.904 - -
Table 4: ROC enrichment (RE) score of our model, docking and other deep learning methods.
The RE score indicates the fraction of the true positive rate (TPR) to the false positive rate
(FPR) at a certain FPR value.
0.5% 1.0% 2.0% 5.0%
ours 60.431 50.106 33.465 16.713
ours w/o attention 57.793 45.636 30.246 15.398
docking 9.307 7.151 5.380 3.803
Ragoza et al.15 42.559 29.654 19.363 10.710
Torng et al.35 44.406 29.748 19.408 10.735
Distinguishing active and inactive binding poses between a ligand and a protein is impor-
tant for interpreting their interaction. Such interpretation helps human experts rationally
modify the ligand to improve its efficacy. Our model can be used for pose prediction be-
cause the 3D conformational information is directly included in the graph representation of
a protein-ligand complex. Table 5 summarizes the performance of our model and docking in
terms of AUROC and PRAUC for the PDBbind test set. Our model improves AUROC and
PRAUC about 0.11 and 0.26 compared to docking respectively. As in the virtual screening
results, the attention algorithm clearly improved the performance in pose prediction.
Figure 1 shows the percentage of complexes with RMSD lower than 2Å identified in
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top-N poses by docking and our model. Our model is 5% to 7% better than docking for the
top-N pose prediction. However, the performance gap between our model and docking for
top-N pose prediction is relatively small compared to the gaps in AUROC and PRAUC. This
means that docking calculation is relatively accurate for ranking poses of different ligands
with an identical protein.
Table 5: AUROC and PRAUC of our model and docking for classification of active and
inactive binding poses.
AUROC PRAUC
ours 0.935 0.772
ours w/o attention 0.927 0.698
docking 0.825 0.509
Figure 1: Percentage of complexes whose RMSD is lower than 2Å identified in top-N poses
by docking and our model
Distribution of predicted activity for a molecular library
The number of potential drug candidates is estimated about 1023 to 1060.45 Among such
large number of molecules, we can safely assume that most of them are inactive to a given
protein. We tested whether our model can reproduce such natural activity distribution.
To do so, 470094 synthetic compounds were obtained from https://www.ibscreen.com. We
preprocessed those synthetic compounds (IBS molecules) as done for the DUD-E dataset.
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The distribution of predicted activities for the IBS molecules to epidermal growth factor
receptor (EGFR) is plotted in Figure 2. It should be noted that EGFR is not included in
the DUD-E training set.
As shown in Figure 2A, our distribution has inactive molecules as a dominant portion,
reproducing the natural population. Also, in Figure 2B, our model correctly predicted the
activity of most of the EGFR active molecules close to 1.0. The EGFR active molecules were
obtained from the DUD-E dataset. In the predicted activity distributions, a small peak is
observed around 1.0 in Figure 2A and 0.0 in Figure 2B. These unnatural peaks may come
from overconfidence of our model, indicating a possibility of slight overfitting.
Figure 2: Activity distributions predicted by our model for the IBS molecules and EGFR
active molecules in the DUD-E dataset.
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Performance on external libraries: ChEMBL and MUV
In the DUD-E dataset, the decoy molecules have considerable structural differences with the
active molecules, so that classifying the DUD-E active and decoy molecules might be rela-
tively easy. On the other hand, experimentally verified inactive compounds share more com-
mon structures with active compounds than the decoys do. Therefore, we further validated
whether our model, trained on the DUD-E dataset, can classify active and inactive com-
pounds which were experimentally verified. The active and inactive molecules with respect
to the DUD-E test proteins were collected from the ChEMBL46 database and preprocessed
in the same way as done for the DUD-E dataset. We labeled the ChEMBL molecules whose
IC50 is smaller than 1.0µ as active and inactive otherwise. As a result, 27389 active and
26939 inactive molecules were obtained. Table 6 shows AUROC of our model and docking
for the ChEMBL molecules. Though our model is still better than docking, the AUROC is
dropped about 0.3 compared to the AUROC of the DUD-E test set. The ChEMBL molecules
and the DUD-E test set share common proteins, so the difference in AUROC only comes
from the difference between the ligand sets.
Table 6: AUROC of our model, docking, and other deep learning models on experimentally
verified active and inactive molecules, and MUV set. The experimentally verified active and
inactive molecules were obtained from the ChEMBL database.
AUROC ChEMBL MUV
ours 0.633 0.536
docking 0.572 0.533
Ragoza et al.15 - 0.518
Torng et al.35 - 0.563
Additionally, we validated our model on the MUV47 dataset. The MUV dataset is de-
signed to remove undesirable bias between active molecules and decoys by optimally spread-
ing active molecules in the chemical space of decoys while maintaining the molecular simi-
larities between active-active molecules and active-decoy molecules. In Table 6, our model,
as with the other deep learning models and docking, shows AUROC close to 0.5 for the
MUV dataset. When a model gives AUROC close to 0.5, it means that the model randomly
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classifies active and inactive molecules. The considerable performance drop for the ChEMBL
and MUV datasets indicates that the deep learning models have common problems with
generalization. We hypothesize that the reason for such common performance drop is that
molecules available in the DUD-E dataset is simply not enough to cover the vast array of
molecules available in the nature.
Conclusion
In this work, we proposed a novel approach for representing protein-ligand complexes using
a specialized graph neural network suited for predicting drug-target interaction. We directly
incorporate the 3D structure of a complex into an adjacency matrix. We also apply a distance-
aware graph attention algorithm with gate augmentation to increase the performance of
our model. The model was trained using the DUD-E dataset for virtual screening and the
PDBbind dataset for pose prediction. As a result, our model outperformed docking and other
deep learning based methods in terms of both virtual screening and pose prediction. Our
model showed AUROC of 0.968 for virtual screening and 0.935 for pose prediction. It also
correctly reproduced the natural population distribution of active and inactive molecules.
Besides the success of our model, it has some limitations in generalization. The perfor-
mance of the model on classifying experimentally verified active and inactive compounds
was significantly reduced compared to the performance on the DUD-E test set. Also, our
model, like docking and other deep learning based models, failed to correctly classify ac-
tive and decoy molecules in the MUV dataset. This may be because the DUD-E training
set cannot effectively span huge chemical space. In addition, because most active molecules
share common scaffolds, it is possible that our model may memorize the structural pattern
within active molecules instead of recognizing proteins. Therefore, our next goal is to achieve
consistent performance on other independent datasets, such as the MUV and the ChEMBL
datasets, as well as the DUD-E test set.
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